Background
==========

During cardiovascular surgery, cardiopulmonary bypass (CPB) time is associated with organ dysfunction such as acute renal failure, myocardial dysfunction, and postoperative lung injury \[[@b1-medscimonit-25-3288]--[@b3-medscimonit-25-3288]\]. Prolonged CPB time induced by complicated cardiac diseases suggested exaggerated inflammatory responses that resulted in harmful mediators which could cause multiple organs dysfunction \[[@b4-medscimonit-25-3288]\]. The lung are among the most vulnerable organs during the perioperative period of cardiovascular surgery with CPB \[[@b5-medscimonit-25-3288]\]. Previous studies showed that 20% of patients who received cardiovascular surgery had acute lung injury during the perioperative period, with a mortality as high as 80% \[[@b6-medscimonit-25-3288]\]. Those patients would receive much more successful treatment if the lung injury were detected earlier \[[@b7-medscimonit-25-3288],[@b8-medscimonit-25-3288]\]. Therefore, a validated biomarker for lung injury in patients who underwent cardiovascular surgery would be helpful for diagnosis and therapy.

Cold-inducible RNA-binding protein (CIRP) is a 172-amino acid protein that belongs to the cold-shock protein family \[[@b9-medscimonit-25-3288]\]. It is expressed constitutively at low levels in various tissues, and is upregulated when tissues are subjected to various stimulations, such as hypothermia, hypoxia, and several types of cancer \[[@b10-medscimonit-25-3288]\]. Furthermore, CIRP plays important roles in tumor suppression or promotion \[[@b11-medscimonit-25-3288],[@b12-medscimonit-25-3288]\] and has deleterious effects during hemorrhagic and septic shock \[[@b13-medscimonit-25-3288]\]. Increased plasma CIRP is associated with poor prognosis of inflammatory-related diseases \[[@b14-medscimonit-25-3288],[@b15-medscimonit-25-3288]\], and blockade of endogenous CIRP attenuates the multiple organ dysfunction \[[@b16-medscimonit-25-3288],[@b17-medscimonit-25-3288]\]. It is well known that CIRP initiates a systemic inflammatory responses that leads to undesirable outcomes. However, in contrast to previous studies, a rat model study of deep hypothermic circulatory arrest showed that CIRP exerts its robust renoprotection roles through inhibiting apoptosis activities \[[@b18-medscimonit-25-3288]\].

To date, the effects of plasma CIRP on patients who underwent cardiovascular surgery are unclear. In the present study we investigated the variation of plasma CIRP and explored the potential causes. We also assessed the correlation between CIRP and parameters that represent the outcomes of organs and explored whether CIRP could be a predictor for lung injury induced by cardiovascular surgery.

Material and Methods
====================

Trial design and participants
-----------------------------

This prospective observational study was conducted at Shanghai General Hospital, Jiaotong University, China. The study protocol and the consent form were approved by the Institutional Ethics Committee of Shanghai General Hospital (Approved number: \[2017\]30). The study was registered at [chictr.org.cn](http://chictr.org.cn) (ChiCTR-IOR-17012381). Informed consent for participation in the study was obtained from patients who received selective cardiac surgery from 19/6/2017 to 28/3/2018 in Shanghai General Hospital. Patients over 18 years of age who underwent cardiovascular surgery with CPB were included. We excluded patients if they met 1 or more of the following criteria: received immunosuppressive therapy (e.g., corticosteroids), had preoperative history of organ dysfunction, had endocrine disease, had an infection, and patient refusal.

Standard anesthesia and cardiopulmonary bypass protocol
-------------------------------------------------------

Anesthesia was managed according to a standard protocol, including induction with fentanyl (5--10 μg/kg), midazolam (0.1 mg/kg), and pipecuronium (0.08 mg/kg). Fentanyl, sevoflurane, and pipecuronium were used during anesthesia maintenance.

The CPB circuit, which was identical for all patients, included a microporous hollow fiber membrane oxygenator (Dideco 901, Dideco Liliput, Italy; Medtronic, Inc, Minneapolis, USA) and a Stockert III roll pump (Stockert Instrument; Munich, Germany). Before aortic cannulation, 400 U/kg heparin was administered with the target kaolin-ACT value more than 480 s. The bypass circuit was primed with lactated Ringer's solution 500 ml, hydroxyethyl starch 500 ml, and heparin 2000 IU. Pump flow rates ranged from 3.0 to 4.0 L·min^−1^·m^−2^. Core temperature was controlled at 30--32°C using a heat exchanger in the bypass circuit. At the end of CPB, to maintain the fluid balance, modified ultrafiltration was used to remove the excess fluid in the body according to the hematocrit (maintenance of hematocrit \>24%) and the monitored blood pressure (aortic blood pressure 85--110/50--80 mmHg, left atrial pressure 5--12 mmHg, and right atrial pressure 5--10 mmHg according to the patient' age and weight). During CPB, myocardial protection strategy was carried out as follows: after aortic cross-clamping, oxygenated blood and cardioplegia solution containing potassium (20 mmol/L) mixed at a 1: 4 ratio at 20°C were infused anterogradely through a cannula at the aortic root to achieve myocardial arrest, and this infusion was repeated every 30--40 min to prevent ischemic damage during CPB.

Blood sample and data collection
--------------------------------

Blood samples were collected 1 day before surgery (T~1~), 6 h after surgery (T~2~), 1 day after surgery (T~3~), 3 days after surgery (T~4~), and 5 days after surgery (T~5~). All samples were centrifugated at 10 000 rpm for 10 min at 4°C. The plasma supernatants were collected and kept at −80°C until use. Inflammatory mediators -- TNF-α, IL-6, IL-10, TLR4, Angiotensin (Ang II), plasminogen activator inhibitor-1(PAI-1), and soluble E-selectin -- were measured by enzyme-linked immunosorbent assay (ELISA) following the manufacturer's (CUSABIO) protocol.

Parameters of patients' demographics information, including gender, age, BMI and ASA physical status; the parameters of clinical data during the surgery, such as CPB time and mechanical ventilation time; the scores of sequential organ failure assessment (SOFA) and acute physiology and chronic health evaluation II (APACHE II) were recorded or calculated according to patients' clinical data at scheduled time points.

Statistical analysis
--------------------

Quantitative data are expressed as mean ±SD or median \[interquartile range (IQR)\], as appropriate. The normality of data distribution was assessed by the Kolmogorov-Smirnov test. The Kruskal-Wallis test or one-way ANOVA was used in statistical analysis to compare differences between groups. Pearson's correlation analysis was conducted to examine the relationship between CIRP and other variables. Multivariate regression analysis was then performed for the independent variables by 'stepwise' method. All the analyses were performed with SPSS software (version 17.0; SPSS Inc., Chicago, USA) and a *P* value of less than 0.05 was considered statistically significant.

Results
=======

Patient characteristics and clinical data
-----------------------------------------

According to the inclusion/exclusion protocol, 31 patients (17 male and 14 female) patients who underwent cardiovascular surgery during the study period were enrolled. The median patient age was 60 years old. The types of surgeries are summarized in [Supplementary Table 1](#s1-medscimonit-25-3288){ref-type="supplementary-material"}. The mean CPB time was 88.8±43.3 min during surgeries. After the patients were admitted to the ICU, the mean mechanical ventilation time was 22.0±23.6 h. The nasopharyngeal temperature, hemorrhage volume, and some clinical parameters were recorded and are shown in the [Table 1](#t1-medscimonit-25-3288){ref-type="table"}.

Plasma CIRP levels and laboratory parameters
--------------------------------------------

We measured the variation of CIRP level during cardiovascular surgery and investigated the correlation between laboratory parameters and CIRP levels. As shown in [Table 2](#t2-medscimonit-25-3288){ref-type="table"}, we collected the laboratory parameters (including blood lactate, lymphocyte counts and serum creatinine) and calculated SOFA and APACHE II scores at different time points ([Table 2](#t2-medscimonit-25-3288){ref-type="table"}). According to the values, even though cardiovascular surgery induced increased lactate, the blood lactate level alone was too low to have effects on outcomes ([Table 2](#t2-medscimonit-25-3288){ref-type="table"}). However, the reduction of lymphocyte counts may represent the immunosuppression state induced by cardiovascular surgery with CPB ([Table 2](#t2-medscimonit-25-3288){ref-type="table"}). As shown in [Figure 1A](#f1-medscimonit-25-3288){ref-type="fig"}, CIRP production was upregulated dramatically and peaked 6 h after cardiovascular surgery (T~2~ time point) and the level of CIRP returned to baseline 5 days after cardiovascular surgery (T~5~ time point); therefore, we analyzed the correlation between CIRP and other parameters at T~2~ time point. Univariate correlation analysis indicated that only SOFA score at T~2~ time point was positively correlated with CIRP production (r=0.472, *P*=0.007) ([Figure 1B](#f1-medscimonit-25-3288){ref-type="fig"}, [Supplementary Table 2](#s2-medscimonit-25-3288){ref-type="supplementary-material"}). Controversially, the SOFA scores at T~2~ timepoint show patients may in a good condition with high CIRP production, perhaps due to the balance between proinflammatory states and organ dysfunction.

Correlations between plasma CIRP level and cytokines production
---------------------------------------------------------------

We found that the levels of IL-6 and IL-10 increased significantly 6 h after cardiovascular surgery. The level of IL-6 returned to baseline at 5 days after surgery, while the IL-10 level remained in high until 5 days after surgery ([Figure 2A--2D](#f2-medscimonit-25-3288){ref-type="fig"}). However, inconsistent with expectation, there was no significant difference among those time points for TNF-α and TLR4, although there was an increasing trend. Univariate correlation analysis ([Supplementary Table 3](#s1-medscimonit-25-3288){ref-type="supplementary-material"}) showed that plasma CIRP level was positively correlated with IL-6 (r=0.567, *P*=0.002) and IL-10 (r=0.412, *P*=0.02) ([Figure 2E--2H](#f2-medscimonit-25-3288){ref-type="fig"}) at T~2~ time point.

CPB time contributes to the production of plasma CIRP
-----------------------------------------------------

We analyzed the correlation between CIRP levels and some clinical factors that can affect CIRP production. Univariate analysis indicated that plasma CIRP level was positively correlated with CPB time, as well as inflammatory cytokines (IL-6 and IL-10), at T~2~ time point ([Supplementary Tables 3, 4](#s1-medscimonit-25-3288){ref-type="supplementary-material"}). To investigate the causes of CIRP upregulation, we used a stepwise multiple linear regression model to adjust age, BMI, operation time, CPB time, mechanical time, temperature (during CPB), and inflammatory cytokines (including TNF-α, IL-6, TLR4, and IL-10). Interestingly, CPB time and IL-6 level were associated with CIRP production (CPB time: *P*=0.013; IL-6: *P*=0.008) ([Table 3](#t3-medscimonit-25-3288){ref-type="table"}). Because IL-6 may secreted by macrophages when stimulated with recombinant CIRP, we proposed that the length of CPB time contributed to the increasement of CIRP production ([Table 3](#t3-medscimonit-25-3288){ref-type="table"}).

Plasma CIRP predicts lung injury induced by cardiopulmonary bypass
------------------------------------------------------------------

As shown in [Figure 3A--3C](#f3-medscimonit-25-3288){ref-type="fig"}, CIRP was associated with Ang II (r=0.438, *P*=0.016), PAI-1(r=0.485, *P*=0.006), and soluble E-selectin (r=0.470, *P*=0.008), which partly reflect lung injuries ([Supplementary Table 5](#s1-medscimonit-25-3288){ref-type="supplementary-material"}). We speculated that CIRP is involved in lung injury during cardiovascular surgery at T~2~ time point. Furthermore, univariate analysis indicated that CIRP production is correlated with severity of lung injury, as reflected by PaO~2~/FiO~2~ ratio at T~2~ time point (r=−0.414, P=0.02) ([Figure 3D](#f3-medscimonit-25-3288){ref-type="fig"}). Therefore, we used CIRP value at this time point for further subsequent multivariable analysis. As expected, in a stepwise multiple linear regression model, plasma CIRP level was independently associated with PaO~2~/FiO~2~ ratio (*P*=0.021, 95%CI: \[−0.203, −0.018\]) after adjusting for age, BMI, operation time, CPB time, mechanical time, hemorrhage volume, blood transfusion, temperature (during CPB), and inflammatory mediators such as TNF-α and IL-6 ([Supplementary Table 6](#s1-medscimonit-25-3288){ref-type="supplementary-material"}).

Discussion
==========

In this study, we investigated the roles of perioperative plasma CIRP in patients who underwent cardiovascular surgery with CPB. We reported for the first time that plasma CIRP was significantly upregulated immediately after CPB. The elevated levels were correlated with inflammatory cytokines IL-6 and IL-10. Furthermore, the length of CPB time was associated with CIRP production, while CIRP level was correlated with severity of lung dysfunction. Therefore, plasma CIRP could serve as a predictor for lung injury after cardiovascular surgery with CPB.

CIRP is a highly conserved RNA-binding nuclear protein. It migrates from nucleus to cytoplasm and then releases into the circulation \[[@b13-medscimonit-25-3288]\]. It exerts its function as a translational regulator for numerous genes or a harmful mediator that induces organ dysfunction \[[@b13-medscimonit-25-3288],[@b19-medscimonit-25-3288]\]. In this study, we found that, compared with preoperative level, plasma CIRP increased immediately after cardiovascular surgery with CPB, and univariate analysis indicated that CIRP is correlated with SOFA scores. These findings suggest CIRP plays detrimental roles during cardiovascular surgery with CPB, in agreement with previous studies \[[@b20-medscimonit-25-3288],[@b21-medscimonit-25-3288]\].

Besides CIRP production, inflammatory cytokines (e.g., IL-6 and IL-10) exhibit a similar variation tendency after CPB, as described previously \[[@b22-medscimonit-25-3288],[@b23-medscimonit-25-3288]\]. Multiple linear regression analysis indicated that the length of CPB time and IL-6 level contribute to CIRP production. However, Wang et al. found that CIRP derived from macrophages induced IL-6 secretion, which exacerbated organ damage \[[@b13-medscimonit-25-3288],[@b16-medscimonit-25-3288]\]. Based on these findings, we speculated that the length of CPB time is an important contributor to upregulation of CIRP. Interestingly, our multiple linear regression analysis found that the temperature value we kept during CPB has little effect on CIRP production, but this finding is inconsistent with previous evidence that CIRP is induced by hypothermia \[[@b18-medscimonit-25-3288],[@b24-medscimonit-25-3288]\]. Considering the hypothermia level during CPB, we speculate that the degree of temperature reduction partly explains this strange phenomenon.

As previous studies described, plasma Ang II, PAI-1, and soluble E-selectin partly indicate lung injury \[[@b25-medscimonit-25-3288]--[@b27-medscimonit-25-3288]\]. In the present study we found that these proteins increased dramatically and were positively correlated with CIRP production after cardiovascular surgery. Considering that CIRP participates in the dysfunction of endothelial cells via activation of the NLRP3 inflammasome \[[@b21-medscimonit-25-3288]\], we speculated that CIRP is correlated with lung injury induced by cardiovascular surgery with CPB. As expected, after adjusting other factors, multiple linear regression analysis indicated that CIRP levels were independently associated with PaO~2~/FiO~2~ and reflect the severity of lung injury \[[@b28-medscimonit-25-3288]\]. These findings strengthen the conclusion that CIRP is a predictor for lung injury after cardiovascular surgery with CPB.

Our study has several limitations. Firstly, inflammatory and stress responses induced by surgeries were different in this study, which may have affected CIRP production. Furthermore, the sample size was too small to make a precise analysis. We did not perform power analysis calculation, although we achieved the expected results. This study is a preliminary investigation of the relationship between CIRP and organ dysfunction during cardiovascular surgery following CPB, and further research is warranted.

Conclusions
===========

CIRP level can act as a biomarker for onset of lung injury after cardiovascular surgery with CPB. Insight into the roles of CIRP in post-cardiovascular surgery provides a potential therapeutic target for pulmonary dysfunction induced by cardiovascular surgery necessitating CPB.

Supplementary Tables
====================

###### 

Surgery type of patients.

  Surgery type       Counts (n, %)
  ------------------ ---------------
  CABG               6 (19.4)
  CABG+MVR           2 (6.5)
  MVR                4 (12.9)
  AVR                6 (19.4)
  MVR+AVR            4 (12.9)
  VSDR               4 (12.9)
  ASD+TVP            1 (3.2)
  Myxomas excision   1 (3.2)
  TAAR               1 (3.2)
  AAR+AVR            2 (6.5)

CABG -- coronary artery bypass grafting; MVR -- mitral valve replacement; AVR -- aortic valve replacement; TVP -- tricuspid valve replacement; VSD -- ventricular septal defect repair; ASD -- atrial septal defect repair; TAAR -- total aortic arch replacement; AAR -- ascending aortic replacement.

###### 

The correlation between CIRP and laboratory parameters.

  Clinical parameters            CIRP                                    
  --------------------- -------- ------------------- ------------------- -------
  Blood lactate         T~2~     0.214               \[−0.152, 0.529\]   0.247
  T^3^                  0.331    \[−0.027, 0.614\]   0.069               
  Lymphocyte count      T~2~     0.03                \[−0.326, 0.382\]   0.865
  T^3^                  −0.228   \[−0.539, 0.138\]   0.218               
  SOFA scores           T~2~     0.472               \[0.1411, 0.708\]   0.007
  T^3^                  0.022    \[−0.335, 0.373\]   0.908               
  APACHE II scores      T~2~     0.160               \[−0.207, 0.487\]   0.391
  T^3^                  0.212    \[−0.154, 0.527\]   0.252               
  Serum creatinine      T~2~     0.139               \[−0.227, 0.470\]   0.457
  T~3~                  −0.346   \[−0.624, 0.009\]   0.056               

###### 

Correlation between cytokines and CIRP level.

  Cytokines           CIRP                                    
  ----------- ------- ------------------- ------------------- -------
  TNF-α       T~2~    −0.006              \[−0.360, 0.369\]   0.972
  T^3^        0.192   \[−0.175, 0.512\]   0.301               
  IL-6        T~2~    0.527               \[0.213, 0.743\]    0.002
  T^3^        0.154   \[−0.212, 0.482\]   0.408               
  TLR4        T~2~    0.288               \[−0.074, 0.583\]   0.116
  T^3^        0.463   \[0.130, 0.702\]    0.009               
  IL-10       T~2~    0.412               \[0.07, 0.669\]     0.02
  T~3~        0.100   \[−0.264, 0.439\]   0.592               

###### 

Correlations between plasma CIRP level and clinical variables.

  Clinical variables                  CIRP                                    
  -------------------------- -------- ------------------- ------------------- -------
  Ages                       T~2~     0.143               \[−0.223, 0.473\]   0.444
  T~3~                       0.119    \[−0.246, 0.454\]   0.524               
  BMI                        T~2~     0.152               \[−0.214, 0.480\]   0.418
  T~3~                       0.08     \[−0.284, 0.421\]   0.676               
  Operation time             T~2~     0.243               \[−0.122, 0.555\]   0.188
  T~3~                       −0.001   \[−0.355, 0.354\]   0.997               
  CPB time                   T~2~     0.507               \[0.186, 0.730\]    0.04
  T~3~                       0.245    \[−0.12, 0.551\]    0.184               
  Mechanical time            T~2~     0.249               \[−0.116, 0.554\]   0.178
  T~3~                       0.005    \[−0.350, 0.359\]   0.978               
  Hemorrhage volume          T~2~     0.008               \[−0.279, 0.426\]   0.653
  T~3~                       −0.224   \[−0.536, 0.14\]    0.226               
  Blood transfusion          T~2~     0.150               \[−0.216, 0.479\]   0.420
  T~3~                       −0.10    \[−0.438, 0.264\]   0.595               
  Fluid replacement          T~2~     0.05                \[−0.313, 0.395\]   0.803
  T~3~                       −0.166   \[−0.492, 0.20\]    0.371               
  Temperature (during CPB)   T~2~     −0.171              \[−0.495, 0.195\]   0.358
  T~3~                       −0.110   \[−0.447, 0.254\]   0.556               
  ICU stay                   T~2~     0.04                \[−0.323, 0.397\]   0.824
  T~3~                       0.104    \[−0.266, 0.448\]   0.583               
  In-hospital stay           T~2~     0.036               \[−0.329, 0.391\]   0.851
  T~3~                       −0.023   \[−0.380, 0.341\]   0.906               

###### 

Correlations between plasma CIRP level and lung injury-related protein.

  Parameter                    CIRP                            
  -------------------- ------- --------------- --------------- -------
  Ang II               T~2~    0.427           −0.086--0.629   0.017
  T^3^                 0.258   −0.107--0.561   0.162           
  PAI-1                T~2~    0.278           −0.085--0.576   0.130
  T^3^                 0.470   0.139--0.707    0.008           
  Soluble E-selectin   T~2~    0.450           0.114--0.692    0.01
  T~3~                 0.214   −0.152--0.528   0.248           

###### 

Multiple linear regression model analysis of independent risk factors associated with PaO~2~/FiO~2~ ratio 6 h after cardiac surgery.

  Variables   Standard regression coefficient   95% CI               P value
  ----------- --------------------------------- -------------------- ---------
  CIRP        0.414                             \[−0.203, −0.018\]   0.021
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![Plasma CIRP levels at scheduled time points and the relationship between CIRP and SOFA scores. (**A**). Plasma CIRP levels at scheduled time points. Data are presented as median \[interquartile range (IQR)\] and analyzed by Kruskal-Wallis test. \*\* *P*\<0.01 *vs.* T~1~ time point, ^\#\#^ *P*\<0.01 *vs.* T~2~ time point. (**B**) CIRP levels association with SOFA scores 6 h after CPB (r=0.472, *P*=0.007).](medscimonit-25-3288-g001){#f1-medscimonit-25-3288}

![Inflammatory cytokines levels at scheduled time points and the correlation between CIRP and cytokines. (**A--D**). Inflammatory cytokines levels at scheduled time points. Data are presented as median \[interquartile range (IQR)\] and analyzed by Kruskal-Wallis test. \*\* *P*\<0.01 *vs.* T~1~ time point, \* *P*\<0.05 *vs.* T~1~ time point, ^\#\#^ *P*\<0.01 *vs.* T~2~ time point. (**E--H**). CIRP positively associated with inflammatory cytokines levels 6 h after CPB. (**F**). CIRP and IL-6: r=0.567, *P*=0.002; (**G**). CIRP and IL-10: r=0.412, *P*=0.02.](medscimonit-25-3288-g002){#f2-medscimonit-25-3288}

![The correlation between CIRP and biomarker that represented lung dysfunction. Data were enrolled at 6 h after cardiovascular surgery and analyzed by Pearson's correlation analysis. (**A**). CIRP and Ang II: r=0.438, *P*=0.016. (**B**). CIRP and PAI-1: r=0.485, *P*=0.006. (**C**). CIRP and soluble E-selectin: r=0.470, *P*=0.008. (**D**). CIRP and PaO~2~/FiO~2~ ratio: r=−0.414, *P*=0.021.](medscimonit-25-3288-g003){#f3-medscimonit-25-3288}

###### 

Patients characteristics and clinical data.

  Characteristics                                                            
  -------------------------------------------------------------------------- ----------------
  Ages (years)                                                               56.5±13.3
  Sex (Male/Female)                                                          17/14
  BMI (Kg/m^2^)                                                              23.1±10.1
  ASA physical status II, III                                                15, 16
  Ejection fraction (%)[a](#tfn2-medscimonit-25-3288){ref-type="table-fn"}   58.68±7.97
  Operation time (min)                                                       225±84.9
  CPB time (min)                                                             88.8±43.3
  Mechanical ventilation time (hours)                                        22.0±23.6
  Hemorrhage volume (ml)                                                     541.9±535.3
  Blood transfusion (ml)                                                     680.6±304.9
  Fluid replacement (ml)                                                     1874.2±1191.4
  Temperature (°C)[b](#tfn3-medscimonit-25-3288){ref-type="table-fn"}        36.6±0.1
  Temperature (°C)[c](#tfn4-medscimonit-25-3288){ref-type="table-fn"}        31.6±1.4
  ICU stay (hours)                                                           42.3 (16--424)
  In-hospital stay (days)                                                    10 (6--32)

Data are presented as the mean ±SD or median (interquartile range) or in parameter counts (n).

Preoperative;

Before surgery;

During surgery.

ASA -- American Society of Anesthesiologists; BMI -- body mass index; CPB -- cardiopulmonary bypass.

###### 

The laboratory parameters during the cardiovascular surgery.

                               T1                  T2                                                                     T3                                                                     T4                                                                                                                T5
  ---------------------------- ------------------- ---------------------------------------------------------------------- ---------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------
  Blood lactate                1.4 (1.1--1.7)      1.9 (1.3--2.6)[a](#tfn7-medscimonit-25-3288){ref-type="table-fn"}      2\. 1 (1.5--2.8)[b](#tfn8-medscimonit-25-3288){ref-type="table-fn"}    1.3 (1.0--1.7)[c](#tfn9-medscimonit-25-3288){ref-type="table-fn"}                                                 1.8 (1.12--2.20)
  Lymphocyte counts (×10^6^)   1.78 (1.41--2.15)   0.49 (0.36--0.69)[b](#tfn8-medscimonit-25-3288){ref-type="table-fn"}   0.47 (0.34--0.77)[b](#tfn8-medscimonit-25-3288){ref-type="table-fn"}   1.19 (0.81--1.34)[b](#tfn8-medscimonit-25-3288){ref-type="table-fn"}                                              1.37 (1.13--1.6)[c](#tfn9-medscimonit-25-3288){ref-type="table-fn"}
  SOFA scores                  1.0 (0--1)          5 (3--7)[b](#tfn8-medscimonit-25-3288){ref-type="table-fn"}            2 (1--5)[b](#tfn8-medscimonit-25-3288){ref-type="table-fn"}            2 (1--3)[a](#tfn7-medscimonit-25-3288){ref-type="table-fn"},[c](#tfn9-medscimonit-25-3288){ref-type="table-fn"}   1 (0--3)[c](#tfn9-medscimonit-25-3288){ref-type="table-fn"}
  APACHE II scores             3 (2--5)            10 (7--14)[b](#tfn8-medscimonit-25-3288){ref-type="table-fn"}          6 (5--8)[b](#tfn8-medscimonit-25-3288){ref-type="table-fn"}            7 (5--9)[b](#tfn8-medscimonit-25-3288){ref-type="table-fn"}                                                       7 (4--8)[b](#tfn8-medscimonit-25-3288){ref-type="table-fn"},[c](#tfn9-medscimonit-25-3288){ref-type="table-fn"}
  Serum creatinine             78 (64--88)         71 (63.4--91.8)                                                        75.9 (64--101)                                                         63.7 (54--80.2)                                                                                                   69.4 (55.2--94.3)

Data are presented as median \[interquartile range (IQR)\]. T~1~ -- 1 day before surgery; T~2~ -- 6 hours after surgery; T~3~ -- 1 day after surgery; T~4~ -- 3 days after surgery; T~5~ -- 5 days after surgery.

*P*\<0.05 *vs.* T~1~ time point;

*P*\<0.01*vs.* T~1~ time point;

*P*\<0.01 *vs.* T~2~ time point.

###### 

Multiple linear regression model analysis of independent risk factors associated with CIRP production 6 h after cardiac surgery.

  Variables   Standard regression coefficient   95% Confidence interval   P Value
  ----------- --------------------------------- ------------------------- ---------
  CPB time    0.394                             \[0.628, 4.918\]          0.013
  IL-6        0.423                             \[−0.407, 2.524\]         0.008
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